30.01.2014

Cristiano Avila Maronna, Advogado associado ao IDDD, mestre e doutor em direito penal pela USP, 2º vice-presidente do IBCCRIM,membro da Rede pense Livre: por uma política de drogas que funcione

Samy Abud Yoshima, administrador de empresas pela FGV-EAESP e mestre em economia pela FGV-EPGE/R

A guerra às drogas, que se apoia no paradigma proibicionista, fracassou miseravelmente. Nunca as drogas ilegais foram tão abundantes, tão baratas, tão acessíveis e tão potentes quanto hoje. Além de não ter sido capaz de suprimir oferta e demanda de psicoativos, a proibição produziu violência, corrupção e encarceramento em massa.

3 February 2014, by Ian Willoughby

In November, the Czech police’s drugs unit raided dozens of “grow shops”, businesses that sell products necessary for the cultivation of marijuana. The police justified the large-scale confiscation of goods on the grounds that a court had ruled it was illegal for the shops to offer in one place everything needed to grow the drug, from seeds to literature. This is disputed by the grow shop owners, including my guest today, Michal Otipka, who runs four in Prague. Before we got on to the legal niceties, I asked Otipka how he’d first got into the business.

3 february 2014

Dutch laws governing marijuana use are so liberal
that even the US pop star Miley Cyrus failed to
spark too much controversy when she lit a joint
on stage in Amsterdam last year.

Now, 35 mayors are urging the government to take
it a step further and let them grow cannabis too,
as a global shift in favour of legalisation is
leaving the once forward-thinking Netherlands lagging behind.

De recente wereldwijde legalisatiegolf heeft GW Pharmaceuticals geen windeieren gelegd. Het aandeel van de op NASDAQ verhandelde farmadochter van Bayer is als een raket omhoog geschoten. Justin Glover, directeur van het Britse farmaceutisch bedrijf, geeft toe dat vorige maand alleen al meer dan 90 miljoen dollar winsten geboekt werden op aandelen[1].

Door Marc Cuyvers

5 februari 2014

Feb 1, 2014

Discovery of new psychiatric medication, whether for the treatment of
depression, autism or schizophrenia, is at a virtual standstill. As just one
example, the antidepressants on the market today are no more effective at
reversing the mood disorder than those that first became available in the
1950s.